#189 Bisphosphonates and Fracture Prevention Trial: Beyond Journal Club with NEJM Group
Core IM | Internal Medicine PodcastShow Notes
Who’s really at risk for fractures, and how should we be treating them? Most fragility fractures occur in patients without osteoporosis. Should we rethink who gets treated? And could just one or two IV infusions (spread years apart) of zoledronate prevent fractures for years? Have the concerns about bisphosphonates been overblown? Find out all the nuances on this episode of Beyond Journal Club, a series brought to you by Core IM in collaboration with NEJM Group.
🔹 Sponsor: Oakstone CME Use the code "CORE25" for 25% off: https://www.coreimpodcast.com/MKSAP 🔹 Transcript & Show Notes Timestamps: (00:59) | Diagnosing Osteoporosis and Hidden Fracture Risk (05:38) | Evolution of Bisphosphonate Use in Osteoporosis Treatment (07:51) | Current Use of Bisphosphonates: Benefits, Risks, and Side Effects (10:31) | Exploring Non-Bisphosphonate Options for Fracture Prevention (11:44) | Teriparatide and Alternative Osteoporosis Medications (14:53) | Inside the Latest Bisphosphonate Clinical Trial (18:07) | Key Findings from the Zoledronate Fracture Prevention Study (22:38) | Public Health Impact of Fracture Prevention Strategies (24:24) | Final Takeaways and Expert Perspectives on Osteoporosis Care
Tags: CoreIM, Internal Medicine, Primary Care, Medical Education, IMCore, Physician Assistant, Nurse Practitioner, Medical Student, Osteoporosis, Fragility Fractures, Zoledronate, Bone Health
Find the best disability insurance for you: https://www.patternlife.com/disability-insurance?campid=497840
Our Sponsors: * Check out ElevenReader and use my code PODCAST for a great deal: https://elevenreader.io
Advertising Inquiries: https://redcircle.com/brands
Privacy & Opt-Out: https://redcircle.com/privacy
More from Core IM | Internal Medicine Podcast
“Should you stop screening for colorectal cancer (CRC) at 75?” This episode explores how to individualize screening decisions based on life expectancy, prior colonoscopy findings, and procedural risks. Learn how to navigate these nuanced conversations, avoid age-based assumptions, and use strategies like mailed FIT kits and offering screening choices to help more patients get screened.
“What’s the best way to screen?” This episode breaks down the pros, limitations, and follow-up needs of FIT, Cologuard, CT colonography, and colonoscopy to help you choose the right CRC screening option for your patients. Also learn practical colonoscopy surveillance intervals based on polyp size, number, and pathology.
“The triglycerides are high. Now what?” This episode breaks down a practical approach to elevated TGs, from knowing when to check ApoB or non-HDL-C to choosing lifestyle changes, lipid-lowering medications, and when to suspect an underlying genetic disorder.
“Too young for colon cancer.” This episode unpacks the red flags of early-onset colorectal cancer (CRC), from blood in the stool and iron deficiency anemia to persistent abdominal pain and changes in bowel habits, and offers practical pearls for closing the clinical loop. Also learn why a “negative” family history may need a yearly refresh.
“It didn’t work.” This episode breaks down practical treatment options (dosing options for naltrexone, acamprosate, topiramate, gabapentin) and counseling pearls to help you meet patients where they are and support their recovery. Also discover blind spots in detox and rehab centers. 🔹Transcript and Show Notes 🔹 Explore ACP’s Substance Use Disorder Education Hub for videos and an AI-powered patient simulation to practice alcohol-use conversations: https://www.coreimpodcast.com/SUDhub Alcohol Use and Chronic Health Conditions Mini Video Series 01:55 | #1: Naltrexone 12:06 | #2 Acamprosate 16:15 | #3: Topiramate 21:12 | #4: Other meds 29:31 | #5: Detox and rehab blind spots